Home » Stocks » VTVT

vTv Therapeutics Inc. (VTVT)

Stock Price: $2.06 USD 0.00 (0.00%)
Updated December 2, 4:00 PM EST - Market closed
Pre-market: $2.00 -0.06 (-2.91%) Dec 3, 8:58 AM

Stock Price Chart

Key Info

Market Cap 104.62M
Revenue (ttm) 22,000
Net Income (ttm) -14.66M
Shares Out 71.05M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $2.06
Previous Close $2.06
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.03
Day's Range 1.90 - 2.11
Day's Volume 957,524
52-Week Range 1.49 - 3.75

More Stats

Market Cap 104.62M
Enterprise Value 106.03M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 71.05M
Float n/a
EPS (basic) -0.34
EPS (diluted) -0.33
FCF / Share -0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.09M
Short Ratio 2.32
Short % of Float n/a
Beta -2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4,755.43
PB Ratio n/a
Revenue 22,000
Operating Income -19.24M
Net Income -14.66M
Free Cash Flow -21.73M
Net Cash -1.41M
Net Cash / Share -0.03
Gross Margin -56,159.09%
Operating Margin -87,468.18%
Profit Margin -66,627.30%
FCF Margin -98,781.82%
ROA -155.17%
ROE n/a
ROIC 2,094.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(239.81% upside)
Current: $2.06
Target: 7.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-77.77%4172.85%-54.1%22.16%-66.49%58.71%-
Gross Profit2.7612.430.290.630.521.550.98
Operating Income-20.07-20.46-50.87-55.02-38.14-28.90-35.83
Net Income-13.04-7.91-16.14-16.35-27.50-36.10-48.20
Shares Outstanding59.9040.7532.8132.8132.81--
Earnings Per Share-0.59-0.69-1.67-1.71-3.32--
Operating Cash Flow-23.02-26.86-44.56-48.21-36.95-30.78-41.68
Capital Expenditures0.240.01-0.03-0.08-0.080.30-0.16
Free Cash Flow-22.78-26.85-44.59-48.29-37.03-30.48-41.84
Cash & Equivalents1.781.6811.9251.5188.001.51-
Total Debt7.1115.7119.5911.06-36.17-
Net Cash / Debt-5.34-14.03-7.6740.4588.00-34.66-
Book Value-49.02-82.85-151-90.95-77.97-499-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name vTv Therapeutics Inc.
Country United States
Employees 26
CEO Stephen Holcombe

Stock Information

Ticker Symbol VTVT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VTVT
IPO Date July 30, 2015


vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Company; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.